Grants and Contributions:
Title:
COVID-19: Pre-clinical development of a therapeutic to treat Acute Respiratory Distress Syndrome in COVID-19
Agreement Number:
967028
Agreement Value:
$6,860,170.00
Agreement Date:
Feb 9, 2021 - May 15, 2023
Description:
Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leakage in Acute Respiratory Distress Syndrome.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M4M 1E4
Reference Number:
172-2020-2021-Q4-967028
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
803496488
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 164 days. The total amended value is 3,371,146 dollars.
Amendment Date
Dec 9, 2022
Recipient's Legal Name:
Mannin Research Inc
Federal Riding Name:
Toronto--Danforth
Federal Riding Number:
35109
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: